Isomorphic Labs was spun out of Google DeepMind, after the tech giant achieved one of the biggest biological breakthroughs in the last 50 years.  Demis Hassabis is at the helm of both Isomorphic and ...

Now Isomorphic Labs, the division within the software giant meant to develop and commercialize the technology, is taking another big step: raising money from an outside investor. Isomorphic ...

AlphaFold’s success would pave the way for Isomorphic Labs, a spinoff focused on AI-driven drug discovery. Isomorphic was founded in 2021, but it wasn’t until yesterday that the company ...

Isomorphic Labs has raised a whopping $600 ... and it already counts Eli Lilly and Novartis among pharma groups that are tapping into its expertise. The London, UK-based company was set up in ...

Bloomberg via Getty Images Hassabis is also the chief executive of DeepMind Technologies, Alphabet’s artificial intelligence research group. Isomorphic Labs has partnered with major ...

Isomorphic Labs has raised $600m in its first external funding round as it pushes forward with artificial intelligence (AI)-driven drug discovery. Thrive Capital led the financing round, with ...

Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Isomorphic has never revealed how much Google ... Shortly after AlphaFold2's release, Murdoch and Hassabis assembled a group of DeepMind employees to explore the ways the AI system could be ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital ...